{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:07:18Z","timestamp":1776085638455,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Autologous stem cell transplantation (ASCT) remains the standard of care for relapsed or refractory Hodgkin lymphoma (R\/R HL), and an increasing proportion of patients receive programmed cell death protein 1 (PD-1) inhibitors prior to transplantation. Engraftment syndrome (ES) is a noninfectious inflammatory complication classically associated with neutrophil recovery; however, early peri-transplant inflammatory manifestations remain poorly characterized and may mimic infectious complications. We aimed to evaluate peri-transplant inflammatory events after ASCT, with particular emphasis on ES-compatible manifestations occurring before neutrophil engraftment and their association with prior PD-1 inhibitor exposure. Materials and Methods: In this single-center retrospective cohort study, 64 consecutive adult patients with HL undergoing ASCT between 2018 and 2025 were analyzed. ES was defined according to Spitzer and Maiolino criteria. Inflammatory manifestations fulfilling these criteria but occurring prior to neutrophil recovery were classified as pre-engraftment syndrome (pre-ES). Clinically significant events were defined by the requirement for systemic corticosteroid therapy. Clinical and laboratory parameters were compared using non-parametric statistical analyses. Results: No cases fulfilled the Spitzer criteria for classical ES, while three patients (4.7%) met the Maiolino criteria, none requiring corticosteroid therapy. Using the broader Maiolino definition, pre-ES was observed in 34 patients (53.1%) when the conventional engraftment time window was disregarded; however, only three patients required systemic corticosteroid therapy. Importantly, all three cases also fulfilled the Spitzer criteria outside the conventional time window, whereas the remaining Maiolino-defined pre-ES cases were self-limiting. All steroid-requiring pre-ES cases occurred exclusively in PD-1-exposed patients, and prior PD-1 therapy was significantly associated with severe pre-ES (p = 0.0007), although this finding is based on a very small number of events. These patients also demonstrated significantly higher early C-reactive protein (CRP) levels. Conclusions: While classical ES after ASCT was uncommon, clinically significant pre-ES occurred exclusively in PD-1-exposed patients. These early inflammatory events may represent a distinct phenotype and require prompt recognition and timely corticosteroid therapy after exclusion of infection. Prospective studies are warranted to validate these findings and refine risk stratification and monitoring strategies.<\/jats:p>","DOI":"10.3390\/medicina62040738","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:38:26Z","timestamp":1776080306000},"page":"738","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-Engraftment Syndrome After Autologous Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma: An Association with Prior PD-1 Inhibitor Exposure"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0225-3145","authenticated-orcid":false,"given":"D\u00e1vid","family":"T\u00f3thfalusi","sequence":"first","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9ta Melani","family":"Csatl\u00f3s","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogl\u00e1rka","family":"Dob\u00f3","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6323-1737","authenticated-orcid":false,"given":"Fanni","family":"Borics","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0453-1709","authenticated-orcid":false,"given":"L\u00e1szl\u00f3 Imre","family":"Pincz\u00e9s","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3507-9997","authenticated-orcid":false,"given":"Zs\u00f3fia","family":"Milt\u00e9nyi","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s00277-023-05354-8","article-title":"Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era\u2014Real-world data from Hungary","volume":"102","author":"Husi","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1182\/blood-2021-154492","article-title":"Autologous Stem Cell Transplant Outcome in Classic Hodgkin Lymphoma Patients in the Era of Post-Transplant Brentuximab Vedotin Consolidation","volume":"138","author":"Chung","year":"2021","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3324\/haematol.2021.278311","article-title":"Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: A 15-year analysis","volume":"107","author":"Nieto","year":"2022","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.bbmt.2015.08.030","article-title":"Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach","volume":"21","author":"Cornell","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_5","first-page":"194","article-title":"Engraftment Syndrome and Acute Graft-versus-Host Disease: A Meta-Analysis","volume":"79","author":"Poonsombudlert","year":"2020","journal-title":"Hawaii. J. Health Soc. Welf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/sj.bmt.1703015","article-title":"Engraftment syndrome following hematopoietic stem cell transplantation","volume":"27","author":"Spitzer","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.bmt.1703855","article-title":"Engraftment syndrome following autologous hematopoietic stem cell transplantation: Definition of diagnostic criteria","volume":"31","author":"Maiolino","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2024-202537","article-title":"Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bakirtas, M., Hindilerden, I.Y., Ulu, B.U., Ekinci, O., Dogu, M.H., Aydogdu, I., Berber, I., Ozatli, D., Demircioglu, S., and Cagliyan, G.A. (2025). Outcomes of Brentuximab Vedotin Monotherapy in Refractory\/Relapsed Classical Hodgkin\u2019s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety. Indian J. Hematol. Blood Transfus., 1\u201311.","DOI":"10.1007\/s12288-025-02093-w"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/bloodadvances.2020003556","article-title":"Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma","volume":"5","author":"Merryman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12032-022-01894-7","article-title":"Engraftment syndrome following Hematopoietic stem cell transplantation: A systematic approach toward diagnosis and management","volume":"40","author":"Maqbool","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3346\/jkms.2008.23.1.98","article-title":"Pre-engraftment Syndrome in Hematopoietic Stem Cell Transplantation","volume":"23","author":"Lee","year":"2008","journal-title":"J. Korean Med. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/sj.bmt.1703075","article-title":"Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation","volume":"27","author":"Capizzi","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1600-0609.2008.01037.x","article-title":"Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome","volume":"80","author":"Dispenzieri","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41409-020-01164-y","article-title":"Prior anti-PD-1 therapy as a risk factor for life-threatening peri-engraftment respiratory distress syndrome in patients undergoing autologous stem cell transplantation","volume":"56","author":"Bai","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12288-017-0899-4","article-title":"Engraftment Syndrome: Clinical Features and Predictive Factors in Autologous Stem Cell Transplant","volume":"34","author":"Sheth","year":"2018","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/bmt.2009.363","article-title":"Engraftment syndrome after auto-SCT: Analysis of diagnostic criteria and risk factors in a large series from a single center","volume":"45","author":"Carreras","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2023-187199","article-title":"Engraftment Syndrome during Autologous Stem Cell Transplant in Hodgkin Lymphoma Patients Treated with Checkpoint Inhibitors: A Multi-Center Retrospective Analysis","volume":"142","author":"Taranto","year":"2023","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"428.e1","DOI":"10.1016\/j.jtct.2025.11.035","article-title":"Impact of Post-Autologous Peripheral Blood Stem Cell Transplant (ASCT)- Granulocyte Colony Stimulating Factor (G-CSF) on Toxicity Profiles in Hodgkin Lymphoma (HL) Patients Receiving Pre-ASCT Immune Checkpoint Inhibitors (ICI)","volume":"32","author":"Khouderchah","year":"2026","journal-title":"Transplant. Cell. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1182\/blood-2023-185289","article-title":"Engraftment Syndrome Incidence after Immune Checkpoint Inhibitor Therapy in Pts with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Single Institutional Review","volume":"142","author":"Odetola","year":"2023","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12185-025-04094-x","article-title":"Engraftment syndrome after PD-1 blockade in classical Hodgkin lymphoma treated by autologous stem cell transplantation","volume":"123","author":"Choi","year":"2026","journal-title":"Int. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1182\/blood-2024-203986","article-title":"Engraftment Syndrome, an Unusual Complication during Autologous Peripheral Stem Cell Transplantation in Relapsed\/Refractory Hodgkin\u2019s Lymphoma Patients Receiving Checkpoint Inhibitors As Salvage Therapy in the Pre-Transplant Setting","volume":"144","author":"Ibrahim","year":"2024","journal-title":"Blood"},{"key":"ref_23","first-page":"324","article-title":"Engraftment Syndrome Following Autologous Stem Cell Transplantation in a Patient Receiving Nivolumab as Salvage Therapy","volume":"42","author":"Demirsoy","year":"2025","journal-title":"Turk. J. Haematol."},{"key":"ref_24","unstructured":"Sachin, M.P., Mundra, M., Mokha, H., Chopra, N., Ray, S., Mehndiratta, S., Singh, A., and Prabhakar, P. (2025, May 15). \u201cUnusual Presentation of Engraftment Syndrome Following Autologous Hematopoietic Stem Cell Transplant in a Nivolumab-Treated Child of relapsed classical Hodgkin lymphoma\u201d: A Case Report. Available online: https:\/\/www.authorea.com\/doi\/full\/10.22541\/au.174729076.65834675\/v1?commit=aa8c10a9953190dd7759ddabc8b1a18ed6840fb5."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/j.jtho.2019.11.015","article-title":"PD-1 Blockers: Staying Long in the Body and Delayed Toxicity Risks","volume":"15","author":"Fukudo","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.12998\/wjcc.v12.i35.6782","article-title":"Cytokine release syndrome induced by anti-programmed death-1 treatment in a psoriasis patient: A dark side of immune checkpoint inhibitors","volume":"12","author":"Fragozo","year":"2024","journal-title":"World J. Clin. Cases"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/738\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:31:22Z","timestamp":1776083482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["medicina62040738"],"URL":"https:\/\/doi.org\/10.3390\/medicina62040738","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,12]]}}}